Scottish Brain Sciences has teamed up with Roche Diagnostics to develop a new blood test for the early detection of Alzheimer’s disease.

The Scottish corporation will work with Roche on several major projects that may result in a substantial impact, according to its CEO and founder Craig Ritchie, according to Edinburgh News.

This work aims to offer a deeper understanding of the initial biological alterations in neurodegenerative diseases by utilising blood-based biomarkers.

Recent evidence indicates that changes might occur in the brains of Alzheimer’s patients before the disease’s symptoms appear.

Early diagnostic tests can be developed by identifying and detecting these changes, helping to offer quicker treatment for patients.

Ritchie was quoted by the news publication as saying: “Early detection of brain changes associated with the earliest stages of neurodegenerative disease like Alzheimer’s disease through blood testing will be transformative in the way we assess, manage and conceptualise clinically Alzheimer’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It will open the door to interventions used very early in the course of disease that are better targeted than current treatments.

“There will be an expectation of big impacts on disease course and even prevention of the late-stage dementia syndromes associated with neurodegenerative disease.”

Alzheimer’s disease is a slow-developing neurodegenerative disorder that worsens as it progresses. It is responsible for 60%–70% of all dementia cases. A common early indication of the disease is struggling to remember recent events.